A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
- Haydon, Andrew (Primary Chief Investigator (PCI))
- Hawkins, Cheryl-Ann (Project Manager)
Project: Research